Zimmer Biomet Holdings, Inc. (NYSE: ZBH) reported a beat on both the top and bottom lines when it delivered its fourth quarter 2022 earnings report on February 3. The surgical appliance and supply com
Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ZBH vs. ABT: Which Stock Is the Better Value Option?

Is Zimmer Biomet a Buy Ahead of Earnings?

08:50am, Wednesday, 01'st Feb 2023
Zimmer Biomet Holdings (NYSE: ZBH) is set to report Q4'22 results on Feb 3, and there are a few things that investors should keep an eye out for.The company is expected to have experienced continued r
Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.
Zimmer Biomet has been struggling, or better said, stagnating for years. Lack of progress has pretty much been the case since the tie-up between Zimmer and Biomet.
Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
Zimmer Biomet Holdings, Inc. reported net sales of $1.67Bn tightened by ~90bps YoY, but reported in constant currency terms, was up 500bps from last year. There was a strong recovery in orthopedic end
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Keri Mattox - Senior Vice President, Chief Communications & Administration Of
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.
Zimmer (ZBH) delivered earnings and revenue surprises of 1.28% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.
Zimmer Biomet (ZBH) gets FDA nod for the Identity Shoulder System to help surgeons perform anatomic, reverse and revision shoulder replacement with precision.
Zimmer (ZBH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE